The initiation of erythropoietin therapy for the purpose of renoprotection may need to be sooner than that for erythropoiesis, because erythropoietin may attenuate renal fibrosis through macrophage adjustment and endothelial cell protection by other uncertain mechanisms (1-9). This evidence concerns the gene EPO and renal fibrosis.